Blade(US:BLDE)2025-11-10 14:02Financial Data and Key Metrics Changes - Revenue rose 36.7% year-over-year to $49.3 million in Q3 2025, with a 29% increase excluding Keystone [11][12] - Medical segment-adjusted EBITDA margin increased to over 15% in Q3 2025, compared to 10.8% in the prior year period [6][12] - Free cash flow from continuing operations was approximately $2 million in the quarter, with expectations for consistent free cash flow generation moving forward [14][17] Business Line Data and Key Metrics Changes - Organ placement services revenue more than doubled year-over-year, indicating strong growth in this segment [11] - Keystone contributed $2.8 million in revenue for half a month, with a full month revenue increase of over 40% year-over-year [12] - The medical segment-adjusted EBITDA margins improved sequentially to 15.1% in Q3 2025, driven by better performance in the fleet [12] Market Data and Key Metrics Changes - Industry-wide NRP adoption rates continued to increase during Q3, with transplants of organs that have undergone NRP approximately doubling versus the prior year [9] - Despite a seasonal decline in industry transplant volumes of approximately 6%, the company achieved a 3% sequential revenue increase [11] Company Strategy and Development Direction - The company has rebranded as Strata Critical Medical and shifted focus to healthcare, aiming for long-term growth and value creation [5] - The integration of Keystone and the launch of a new clinical services division positions the company as an end-to-end organ recovery platform [8] - The strategy includes co-locating resources to reduce costs and improve service delivery efficiency [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong demand seen in Q3, leading to an increase in 2025 revenue guidance to $185 million-$195 million [17] - The company anticipates continued growth driven by new technology and evolving regulations in the transplant industry [23] - Management noted that the seasonal decline in transplant volumes is expected and has been historically observed, but the company is growing through this seasonality [40] Other Important Information - The company ended the quarter with no debt and approximately $76 million in cash and short-term investments [16] - A legal provision was booked during the quarter for ongoing litigation related to the go-public transaction [17] Q&A Session Summary Question: Can you provide a disaggregation of where the growth came from in terms of revenue during Q3? - Management indicated that growth was a mix of new customer acquisition and strength within existing customers, with a broadened suite of services contributing to revenue growth [21][22] Question: Do you see the growth coming from similar directions in the future? - Management expects continued customer acquisition and market share consolidation, supported by a favorable industry growth trajectory [23] Question: What should be expected in terms of fleet margin and maintenance impact? - Management noted that scheduled maintenance events have decreased and margins are expected to improve sequentially [24] Question: How many individual customers are being served now post-Keystone acquisition? - Management stated that there are almost 250 different customers across the cardiac care and transplant businesses, providing geographic diversity [30] Question: Is there any customer that constitutes 5% or more of revenues? - Management did not disclose specific customer revenue contributions but emphasized a diversified customer base [31] Question: Will there be a breakdown of logistics versus perfusionist services? - Management indicated that a pro forma 2025 business mix will be provided, reflecting the expected shift towards fast-growing subsectors of the transplant industry [35][36]